{
    "hands_on_practices": [
        {
            "introduction": "When screening large populations for rare genetic variants, even highly accurate tests can generate a surprising number of false positives. This exercise demonstrates this principle by guiding you through the calculation of the Positive Predictive Value (PPV), which represents the true probability that a positive test result is correct. Understanding PPV is the first critical step in interpreting screening results and underscores the universal need for confirmatory testing before a definitive diagnosis is made .",
            "id": "5055933",
            "problem": "A regional health system is implementing opportunistic screening for incidental pathogenic variants in a set of medically actionable genes recommended for disclosure. The screening assay has analytically validated test characteristics and is used in individuals undergoing genome sequencing for non-genetic indications. Assume that the true prevalence of carrying a pathogenic variant in the actionable set for this population is $Prev = 0.002$. The assay’s sensitivity (the probability of a positive test given the variant is truly present) is $Se = 0.99$, and its specificity (the probability of a negative test given the variant is truly absent) is $Sp = 0.995$.\n\nUsing Bayes’ theorem and the canonical definitions of sensitivity, specificity, and prevalence, derive an expression for the Positive Predictive Value (PPV), defined as the probability that a person truly carries a pathogenic variant given a positive screen. Then compute the numeric value of $PPV$ for the parameters given. Round your answer to four significant figures and express it as a decimal (not a percentage). Finally, based on this value, briefly explain whether immediate disclosure of a positive incidental finding is justified, or if confirmatory testing prior to disclosure is indicated, grounding your reasoning in the quantitative result and standard principles for managing incidental and secondary genomic findings in medical genetics. Do not include any qualitative interpretation in your final numeric answer.",
            "solution": "Let $D$ be the event that a person truly carries a pathogenic variant, and let $D^c$ be the event that the person does not. Let $T^+$ be the event of a positive test result and $T^-$ be the event of a negative test result.\n\nThe givens from the problem statement are:\n1.  The prevalence of the condition, $P(D) = Prev = 0.002$.\n2.  The sensitivity of the assay, $P(T^+ | D) = Se = 0.99$.\n3.  The specificity of the assay, $P(T^- | D^c) = Sp = 0.995$.\n\nFrom these, we can deduce:\n- The probability of not having the condition is $P(D^c) = 1 - P(D) = 1 - Prev = 1 - 0.002 = 0.998$.\n- The probability of a positive test in a person without the variant (the false positive rate) is $P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - Sp = 1 - 0.995 = 0.005$.\n\nThe objective is to derive an expression for the Positive Predictive Value (PPV), which is defined as the probability that a person has the variant given a positive test result, denoted $P(D | T^+)$.\n\nUsing Bayes' theorem, the PPV is given by:\n$$PPV = P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)}$$\nThe denominator, $P(T^+)$, is the total probability of a positive test. It can be found using the law of total probability, summing the probabilities of a true positive and a false positive:\n$$P(T^+) = P(T^+ \\cap D) + P(T^+ \\cap D^c)$$\nUsing the definition of conditional probability, this can be expanded to:\n$$P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)$$\nSubstituting this expression for $P(T^+)$ back into the Bayes' theorem formula for PPV, we get:\n$$PPV = \\frac{P(T^+ | D) P(D)}{P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)}$$\nThis is the general expression for PPV. Now, we substitute the standard symbols for prevalence, sensitivity, and specificity. The derived expression for PPV is:\n$$PPV = \\frac{Se \\cdot Prev}{Se \\cdot Prev + (1 - Sp) \\cdot (1 - Prev)}$$\nThis completes the derivation part of the problem.\n\nNext, we compute the numeric value of the PPV using the provided parameters: $Prev = 0.002$, $Se = 0.99$, and $Sp = 0.995$.\n$$PPV = \\frac{0.99 \\cdot 0.002}{0.99 \\cdot 0.002 + (1 - 0.995) \\cdot (1 - 0.002)}$$\nFirst, we calculate the numerator and the terms in the denominator:\nNumerator (True Positives probability): $0.99 \\cdot 0.002 = 0.00198$.\nDenominator term 1 (True Positives probability): $0.00198$.\nDenominator term 2 (False Positives probability): $(0.005) \\cdot (0.998) = 0.00499$.\nNow, we compute the final value:\n$$PPV = \\frac{0.00198}{0.00198 + 0.00499} = \\frac{0.00198}{0.00697}$$\n$$PPV \\approx 0.28407459...$$\nRounding to four significant figures, the numeric value is $0.2841$.\n\nFinally, we address the clinical interpretation. A Positive Predictive Value of $0.2841$ means that when a patient receives a positive screening result, there is only a $28.41\\%$ chance that they truly have the pathogenic variant. Conversely, there is a $71.59\\%$ chance that the result is a false positive. According to standard principles for managing incidental and secondary genomic findings, such as those established by the American College of Medical Genetics and Genomics (ACMG), a screening result is not considered a definitive diagnosis. Given that a positive result in this scenario is substantially more likely to be false than true, immediate disclosure of this finding to the patient would be inappropriate and potentially harmful, as it could cause significant distress and lead to unwarranted medical decisions. The low-to-moderate PPV mandates that a confirmatory test be performed using an independent and analytically validated method (e.g., Sanger sequencing) to verify the finding. Only a confirmed positive result should be disclosed to the patient as a definitive diagnosis. Therefore, confirmatory testing prior to disclosure is unequivocally indicated.",
            "answer": "$$\\boxed{0.2841}$$"
        },
        {
            "introduction": "After a genetic variant is identified, a crucial step is to determine if it is genuinely pathogenic. This practice problem simulates a key process in modern variant interpretation, where you will use population genetics data to assess whether a variant is too common to be the cause of a rare genetic disorder . By calculating a maximum credible allele frequency based on disease parameters and comparing it to observed data, you will apply the quantitative reasoning behind the ACMG/AMP \"Benign Strong 1\" (BS1) criterion.",
            "id": "5055885",
            "problem": "A clinical exome reveals an incidental heterozygous variant in the gene _MYH7_, which is part of the American College of Medical Genetics and Genomics (ACMG) Secondary Findings list version $3$ and is associated with autosomal dominant hypertrophic cardiomyopathy. Population data from the Genome Aggregation Database (gnomAD) Non-Finnish European (NFE) cohort report an allele count of $AC=75$ and an allele number of $AN=250000$ for the variant, yielding a cohort allele frequency $f$.\n\nAssume the following disease architecture for hypertrophic cardiomyopathy: total disease prevalence in adults $\\pi=2\\times 10^{-3}$, variant penetrance $\\rho=0.6$ for heterozygotes, proportion of disease attributable to _MYH7_ in this population $g=0.4$, and a conservative upper bound on the fraction of _MYH7_ cases attributable to any single pathogenic variant $a=0.02$. Use Hardy–Weinberg equilibrium and the definition of penetrance to derive, from first principles, the maximum credible allele frequency $f^{*}$ at which a single pathogenic variant could plausibly exist without exceeding the disease burden it could cause. Then calculate $f$ from the gnomAD counts, compare $f$ to $f^{*}$, and define a disclosure decision variable $D$ using the following rule based on the ACMG/Association for Molecular Pathology (AMP) Benign Strong $1$ (BS1) criterion and an institutional policy that discloses only pathogenic or likely pathogenic secondary findings:\n\n- If $f>f^{*}$ (i.e., BS1 applies, favoring a benign classification in the absence of other pathogenic evidence), set $D=0$ (do not disclose).\n- If $f\\le f^{*}$ (BS1 does not apply), set $D=1$ (disclose, given gene actionability and absent conflicting benign evidence).\n\nReport the single numeric value of $D$ as your final answer. No rounding is required and no units should be included.",
            "solution": "The problem requires the determination of a disclosure decision variable, $D$, for an incidental genetic variant. This decision is based on a comparison between the variant's observed allele frequency, $f$, and a calculated maximum credible allele frequency, $f^{*}$, for a pathogenic variant. If the observed frequency exceeds this maximum ($f > f^{*}$), the variant is too common to be a pathogenic cause of the disease under the given model, triggering the Benign Strong 1 (BS1) criterion and leading to a decision not to disclose ($D=0$). Otherwise ($f \\le f^{*}$), the variant's frequency is consistent with pathogenicity, and disclosure is warranted ($D=1$).\n\nThe first step is to derive an expression for $f^{*}$ from first principles.\nLet $\\pi$ be the total prevalence of the disease (hypertrophic cardiomyopathy) in the adult population.\nLet $g$ be the proportion of the disease attributable to pathogenic variants in the gene `MYH7`.\nThe prevalence of the disease specifically caused by `MYH7` variants is therefore $\\pi_{MYH7} = \\pi \\cdot g$.\n\nThe problem states that $a$ is a conservative upper bound on the fraction of `MYH7` cases attributable to any single pathogenic variant. Therefore, the maximum disease prevalence that can be explained by a single pathogenic `MYH7` variant, $\\pi_{variant}$, is given by:\n$$ \\pi_{variant} = \\pi_{MYH7} \\cdot a = \\pi \\cdot g \\cdot a $$\n\nNext, we relate this disease prevalence to the allele frequency of the variant, $f^{*}$, using principles of population genetics. The disease is autosomal dominant. According to the Hardy-Weinberg equilibrium principle, for a rare allele with frequency $f^{*}$, the population consists of individuals with three genotypes: wild-type/wild-type, wild-type/variant (heterozygote), and variant/variant (homozygote). Their frequencies are approximately $(1-f^{*})^2$, $2f^{*}(1-f^{*})$, and $(f^{*})^2$, respectively.\n\nFor a rare disease allele, $f^{*} \\ll 1$, which allows for simplification. The frequency of heterozygotes can be approximated as $2f^{*}(1-f^{*}) \\approx 2f^{*}$. The frequency of homozygotes, $(f^{*})^2$, is negligible compared to the heterozygote frequency. We can therefore reasonably assume that nearly all individuals carrying the variant are heterozygotes.\n\nLet $\\rho$ be the penetrance of the variant, defined as the probability that a heterozygous individual will manifest the disease. The prevalence of the disease caused by this specific variant, $\\pi_{variant}$, can be expressed as the frequency of carriers multiplied by the penetrance:\n$$ \\pi_{variant} \\approx (\\text{frequency of heterozygotes}) \\times \\rho \\approx (2f^{*}) \\cdot \\rho $$\n\nBy equating the two derived expressions for $\\pi_{variant}$, we can establish a relationship between the disease parameters and the maximum credible allele frequency, $f^{*}$:\n$$ \\pi \\cdot g \\cdot a = 2f^{*}\\rho $$\n\nSolving for $f^{*}$ yields the formula for the maximum credible allele frequency for a pathogenic variant under the specified model:\n$$ f^{*} = \\frac{\\pi \\cdot g \\cdot a}{2\\rho} $$\n\nNow, we substitute the given values into this formula to calculate the numerical value of $f^{*}$:\n- Total disease prevalence, $\\pi = 2 \\times 10^{-3}$\n- Proportion of disease due to `MYH7`, $g = 0.4$\n- Fraction of `MYH7` cases due to a single variant, $a = 0.02$\n- Variant penetrance, $\\rho = 0.6$\n\n$$ f^{*} = \\frac{(2 \\times 10^{-3}) \\cdot (0.4) \\cdot (0.02)}{2 \\cdot (0.6)} = \\frac{2 \\times 10^{-3} \\cdot 0.008}{1.2} = \\frac{1.6 \\times 10^{-5}}{1.2} $$\nTo simplify this fraction:\n$$ f^{*} = \\frac{1.6}{1.2} \\times 10^{-5} = \\frac{16}{12} \\times 10^{-5} = \\frac{4}{3} \\times 10^{-5} $$\n\nThe next step is to calculate the observed allele frequency, $f$, from the provided gnomAD population data:\n- Allele Count, $AC = 75$\n- Allele Number, $AN = 250000$\n\nThe allele frequency $f$ is the ratio of the allele count to the total number of alleles genotyped:\n$$ f = \\frac{AC}{AN} = \\frac{75}{250000} = \\frac{3 \\times 25}{100 \\times 2500} = \\frac{3}{10000} = 3 \\times 10^{-4} $$\n\nFinally, we compare the observed frequency $f$ with the maximum credible frequency $f^{*}$ to determine the value of the decision variable $D$.\n- $f = 3 \\times 10^{-4}$\n- $f^{*} = \\frac{4}{3} \\times 10^{-5}$\n\nTo facilitate comparison, we express both frequencies with the same power of $10$:\n- $f = 3 \\times 10^{-4} = 30 \\times 10^{-5}$\n- $f^{*} = \\frac{4}{3} \\times 10^{-5} \\approx 1.33 \\times 10^{-5}$\n\nComparing the two values, we see that $30 > \\frac{4}{3}$. Therefore, $f > f^{*}$.\n\nThe rule for the disclosure decision variable $D$ is:\n- If $f > f^{*}$, set $D=0$.\n- If $f \\le f^{*}$, set $D=1$.\n\nSince our calculated $f$ is greater than $f^{*}$, the condition for the BS1 criterion is met. The allele is too frequent in the general population to be a plausible cause of the disease given the specified parameters of prevalence, genetic architecture, and penetrance. According to the problem's rule, we do not disclose the finding.\nThus, we set $D=0$.",
            "answer": "$$\\boxed{0}$$"
        },
        {
            "introduction": "The decision to report an incidental finding hinges on its \"clinical actionability\"—whether knowledge of the variant can lead to an intervention that provides a net health benefit. This exercise provides a hands-on approach to quantifying actionability using the concept of Quality-Adjusted Life Years (QALYs) . You will build a model that weighs the benefits of preventive action against its costs and risks, providing a formal framework for the ethical and clinical justification of returning secondary genomic findings.",
            "id": "5055918",
            "problem": "A clinical laboratory performing clinical exome sequencing identifies a pathogenic variant in a cancer susceptibility gene as a secondary finding in an asymptomatic adult. The laboratory must decide whether returning this secondary finding meets actionability criteria based on expected net benefit. In this setting, returning the result leads to an offer of a prophylactic intervention with known effects; if the result is not returned, no prophylaxis is undertaken. Assume the following quantities are known and scientifically well-validated:\n\n- Penetrance is defined as the cumulative probability that a carrier develops the associated cancer by age at risk, denoted by $p$. Here, $p = 0.40$ to age risk.\n- The one-time occurrence of the cancer causes an average loss of $L$ Quality-Adjusted Life Years (QALYs), denoted $L = 12$.\n- If undertaken, prophylaxis yields a relative risk reduction denoted by $r$, with $r = 0.80$.\n- Real-world adherence to prophylaxis is imperfect: the probability that a carrier adheres sufficiently to obtain the risk reduction is $a = 0.70$.\n- Prophylaxis carries a small quality-of-life decrement while adhered, denoted by $s$ QALYs per year, applied over $D$ years. Here, $s = 0.020$ QALYs per year and $D = 20$ years.\n- There is no disutility from simply receiving the result beyond what is captured in $s$, and no additional mortality or morbidity from prophylaxis beyond the quality-of-life decrement $s$. Ignore discounting and background mortality unrelated to the variant.\n- The actionability threshold used by the laboratory is a net expected benefit of at least $T = 0.050$ QALYs per carrier when the result is returned versus not returned.\n\nStarting from the definitions of penetrance and relative risk reduction, and using the expected value principle that the expected net benefit is the sum over outcomes of probability times consequence, derive an expression for the expected net QALY benefit of returning the result (which enables prophylaxis) versus not returning the result. Then evaluate this expression numerically using the values above. Finally, report the expected net QALY benefit. Express your final answer in Quality-Adjusted Life Years (QALYs) and round your answer to four significant figures.",
            "solution": "### Derivation of the Expected Net QALY Benefit\nThe goal is to calculate the expected net benefit in Quality-Adjusted Life Years (QALYs) of returning the secondary finding versus not returning it. This is the difference between the expected QALYs in the two scenarios. Let $\\Delta E$ represent this net benefit.\n\n$\\Delta E = E[\\text{QALYs} | \\text{Result Returned}] - E[\\text{QALYs} | \\text{Result Not Returned}]$\n\nLet us analyze each term separately, considering a carrier of the pathogenic variant. We establish a baseline of $0$ QALYs lost for a carrier who does not develop cancer and does not undergo prophylaxis. All outcomes will be measured as a change relative to this baseline.\n\n**Scenario 1: Result Not Returned**\nIf the result is not returned, the individual is unaware of their risk and does not undertake prophylaxis. The only potential QALY-modifying event is the development of the associated cancer.\n-   The probability of developing cancer is the penetrance, $p$.\n-   The consequence of developing cancer is a loss of $L$ QALYs.\n-   The expected QALYs in this scenario, $E_{NR}$, is the probability of the outcome multiplied by its consequence:\n$$E_{NR} = p \\times (-L) + (1-p) \\times 0 = -pL$$\n\n**Scenario 2: Result Returned**\nIf the result is returned, the individual is offered prophylaxis. Their decision to adhere introduces two sub-pathways.\n-   With probability $a$, the individual adheres to prophylaxis.\n-   With probability $1-a$, the individual does not adhere.\n\nLet's analyze the expected QALYs for each sub-pathway.\n\n**Sub-pathway 2a: Adherence to Prophylaxis (occurs with probability $a$)**\nAn adherent individual incurs a definite cost from prophylaxis and gains a reduction in cancer risk.\n-   The cost of prophylaxis is a decrement of $s$ QALYs per year for $D$ years, for a total deterministic loss of $sD$ QALYs.\n-   Prophylaxis provides a relative risk reduction of $r$. The initial risk (penetrance) of $p$ is reduced to a new risk of $p_{new} = p(1-r)$.\n-   The expected QALY loss from cancer for an adherent individual is $p_{new} \\times L = p(1-r)L$.\n-   The total expected QALYs for an adherent individual, $E_{Adherent}$, is the sum of the loss from prophylaxis and the expected loss from the reduced cancer risk:\n$$E_{Adherent} = -sD + (p(1-r) \\times (-L)) = -sD - p(1-r)L$$\n\n**Sub-pathway 2b: Non-adherence to Prophylaxis (occurs with probability $1-a$)**\nA non-adherent individual does not incur the cost of prophylaxis but also does not gain its benefit. Their situation is identical to the \"Result Not Returned\" scenario.\n-   The cost of prophylaxis is $0$, as the decrement $s$ applies only while adhered.\n-   The cancer risk remains the original penetrance, $p$.\n-   The expected QALYs for a non-adherent individual, $E_{Non-Adherent}$, is:\n$$E_{Non-Adherent} = p \\times (-L) = -pL$$\n\n**Overall Expected QALYs for Scenario 2**\nThe total expected QALYs when the result is returned, $E_R$, is the weighted average of the outcomes for adherents and non-adherents, using the law of total expectation:\n$$E_R = a \\times E_{Adherent} + (1-a) \\times E_{Non-Adherent}$$\n$$E_R = a(-sD - p(1-r)L) + (1-a)(-pL)$$\n\n**Calculating the Net Expected Benefit $\\Delta E$**\nNow we compute the difference $\\Delta E = E_R - E_{NR}$:\n$$\\Delta E = \\left[ a(-sD - p(1-r)L) + (1-a)(-pL) \\right] - (-pL)$$\nLet's expand and simplify the expression:\n$$\\Delta E = -asD - ap(1-r)L - (1-a)pL + pL$$\n$$\\Delta E = -asD - apL + aprL - pL + apL + pL$$\nThe terms $-apL$, $+apL$, $-pL$, and $+pL$ cancel out, leaving:\n$$\\Delta E = aprL - asD$$\nThis can be factored to yield the final expression for the expected net QALY benefit:\n$$\\Delta E = a (prL - sD)$$\nThis expression is intuitive: the net benefit is the expected gain for the fraction of the population that adheres ($a$). For this group, the benefit is the absolute risk reduction ($pr$) multiplied by the loss from cancer ($L$), minus the QALY cost of the intervention ($sD$).\n\n### Numerical Evaluation\nWe substitute the given values into the derived expression:\n-   $a = 0.70$\n-   $p = 0.40$\n-   $r = 0.80$\n-   $L = 12$\n-   $s = 0.020$\n-   $D = 20$\n\nFirst, calculate the expected QALYs gained from cancer prevention for an adherent individual:\n$$prL = 0.40 \\times 0.80 \\times 12 = 0.32 \\times 12 = 3.84$$\nNext, calculate the QALYs lost due to the prophylaxis burden for an adherent individual:\n$$sD = 0.020 \\times 20 = 0.40$$\nThe net benefit for an adherent individual is $prL - sD = 3.84 - 0.40 = 3.44$ QALYs.\nFinally, we weigh this benefit by the probability of adherence to find the expected net benefit for any carrier offered the intervention:\n$$\\Delta E = a(prL - sD) = 0.70 \\times (3.44) = 2.408$$\n\nThe expected net QALY benefit is $2.408$ QALYs. This value is significantly greater than the actionability threshold of $T=0.050$ QALYs, indicating that returning this secondary finding is clinically actionable under the specified model. The problem asks for the expected net QALY benefit, which is $2.408$. This value is already stated to four significant figures.",
            "answer": "$$\\boxed{2.408}$$"
        }
    ]
}